Astellas and Cell Signaling Technology partnered to pool their respective IP covering the EML4-ALK oncogenic fusion protein to develop and commercialize cancer diagnostics and therapeutics worldwide

Cell Signaling Technology Inc.

U.S. / Tools, Services, and Manufacturing

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced